SPOTLIGHT: Schering inks deal with Avid
Schering has inked a deal with Avid Radiopharmaceuticals to develop new imaging agents for Alzheimer's. The absence of a definitive diagnosis for Alzheimer's has hindered the development of new therapies, says Schering. Report


SHARE
WITH: